Molecule Details
| InChIKey | MUTNCGKQJGXKEM-UHFFFAOYSA-N |
|---|---|
| Canonical SMILES | CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(C(=O)O)cc3)ccc21 |
| Clinical Status | Data-mined Candidate |
| Targets (Human+Pathogen) | 2 |
| Pfam Stratification | Homologous |
| Avg pChEMBL | 7.58 |
| Source | ChEMBL;BindingDB |
2D Structure
Activity Profile
DrugBank Annotations
| DrugBank ID | DB04942 |
|---|---|
| Drug Name | Tamibarotene |
| CAS Number | 94497-51-5 |
| Groups | investigational |
| ATC Codes | nan |
| Description | Tamibarotene is a novel synthetic retinoid for acute promyelocytic leukaemia (APL). Tamibarotene is currently approved in Japan for treatment of recurrent APL, and is undergoing clinical trials in the United States. |
Categories: Acids, Carbocyclic Benzene Derivatives Naphthalenes
Cross-references: BindingDB: 50061625 ChEBI: 32181 CHEMBL25202 ChemSpider: 97231 Guide to Pharmacology: 2648 IUPHAR: 2648 C12864 D01418 PDB: A80 PharmGKB: PA164743464 PubChem:108143 PubChem:46509039 Therapeutic Targets Database: DAP000461 Wikipedia: Tamibarotene ZINC: ZINC000000538415